Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660036 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00660036 is a Phase 1 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 5 participants.
The verdict
NCT00660036, a Phase 1 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.
Interventions
- DRUG Etoposide
- DRUG Mitoxantrone
- DRUG Gemtuzumab ozogamicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660036
The ClinicalTrials.gov registry entry for NCT00660036 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT00660036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660036 about?
NCT00660036 is a clinical study titled "Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia". The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.
What is the current status of trial NCT00660036?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-09. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00660036?
The interventions under investigation include: Etoposide (DRUG), Mitoxantrone (DRUG), Gemtuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00660036?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.